Police & Firemen s Retirement System of New Jersey Increases Holdings in Guardant Health, Inc. $GH

Police & Firemen s Retirement System of New Jersey increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,006 shares of the company’s stock after purchasing an additional 1,247 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Guardant Health were worth $1,405,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Guardant Health by 0.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock worth $152,014,000 after buying an additional 13,088 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Guardant Health by 100.4% in the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after acquiring an additional 1,414,381 shares during the period. Invesco Ltd. raised its holdings in shares of Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock worth $119,053,000 after purchasing an additional 1,403,670 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Guardant Health by 6.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after purchasing an additional 164,263 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Guardant Health by 49.6% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030,638 shares of the company’s stock valued at $105,674,000 after purchasing an additional 673,411 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider John G. Saia sold 8,996 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $96.25, for a total transaction of $865,865.00. Following the transaction, the insider directly owned 43,172 shares of the company’s stock, valued at $4,155,305. This trade represents a 17.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 313,161 shares of company stock valued at $18,996,062 over the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Trading Up 0.8%

Shares of GH opened at $100.30 on Friday. Guardant Health, Inc. has a 12 month low of $29.91 and a 12 month high of $110.00. The stock’s 50 day moving average is $73.93 and its two-hundred day moving average is $58.08. The firm has a market cap of $12.64 billion, a P/E ratio of -31.25 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same period last year, the company earned ($0.88) EPS. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on GH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Wednesday, October 8th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target for the company in a research report on Thursday, September 25th. Raymond James Financial boosted their price target on Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 31st. Wells Fargo & Company initiated coverage on shares of Guardant Health in a research note on Monday, September 22nd. They set an “overweight” rating and a $72.00 price objective on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.14.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.